Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029360 | 0.85 | QDPR (0.50) | PDE4APDE4BPDE4CPDE4DHIF1A | |
| SCHEMBL9327374 | 0.80 | PDE4B (0.67) | PDE4APDE4BPDE4CPDE4DVEGFA | |
| SCHEMBL9327377 | 0.80 | PDE4B (0.67) | PDE4APDE4BPDE4CPDE4DVEGFA | |
| SCHEMBL9327384 | 0.80 | PDE4B (0.67) | PDE4APDE4BPDE4CPDE4DVEGFA | |
| SCHEMBL14492330 | 0.77 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DQDPR | |
| SCHEMBL12856197 | 0.74 | QDPR (0.44) | PDE4APDE4BPDE4CPDE4DKDM1A | |
| SCHEMBL10208059 | 0.73 | QDPR (0.70) | PDE4APDE4BPDE4CPDE4DQDPR | |
| SCHEMBL14747863 | 0.73 | CYP2C9 (0.47) | PDE4APDE4BPDE4CPDE4DQDPR | |
| SCHEMBL26473246 | 0.71 | HTR2A (0.67) | PDE4B | |
| SCHEMBL26473252 | 0.71 | HTR2A (0.67) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275413-B1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |